ALRN stock icon

Aileron Therapeutics
ALRN

$3.22
0.92%
 

About: Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.

Employees: 3

0
Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

238% more capital invested

Capital invested by funds: $3.24M [Q4 2023] → $11M (+$7.71M) [Q1 2024]

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

15% more funds holding

Funds holding: 20 [Q4 2023] → 23 (+3) [Q1 2024]

12.78% more ownership

Funds ownership: 21.75% [Q4 2023] → 34.53% (+12.78%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$19
490%
upside
Avg. target
$19
490%
upside
High target
$19
490%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Ladenburg Thalmann
Aydin Huseynov
490%upside
$19
Buy
Maintained
18 Apr 2024

Financial journalist opinion